TY  - GEN
AU  - Provencio,Mariano
AU  - Cruz Mora,Miguel Á
AU  - Gómez-Codina,José
AU  - Quero Blanco,Cristina
AU  - Llanos,Marta
AU  - García-Arroyo,Francisco R
AU  - de la Cruz,Luis
AU  - Gumá Padró,Josep
AU  - Delgado Pérez,Juan R
AU  - Sánchez,Antonio
AU  - Alvarez Cabellos,Ruth
AU  - Rueda,Antonio
TI  - Consolidation treatment with Yttrium-90 ibritumomab tiuxetan after new induction regimen in patients with intermediate- and high-risk follicular lymphoma according to the follicular lymphoma international prognostic index: a multicenter, prospective phase II trial of the Spanish Lymphoma Oncology Group
SN  - 1029-2403
PY  - 2014///0813
KW  - Adult
KW  - Aged
KW  - Antibodies, Monoclonal
KW  - administration & dosage
KW  - Antibodies, Monoclonal, Murine-Derived
KW  - adverse effects
KW  - Antineoplastic Agents
KW  - Antineoplastic Combined Chemotherapy Protocols
KW  - Consolidation Chemotherapy
KW  - Cyclophosphamide
KW  - Doxorubicin
KW  - Female
KW  - Humans
KW  - Induction Chemotherapy
KW  - Lymphoma, Follicular
KW  - drug therapy
KW  - Male
KW  - Medication Adherence
KW  - Middle Aged
KW  - Neoplasm Grading
KW  - Neoplasm Staging
KW  - Prednisone
KW  - Prognosis
KW  - Risk Factors
KW  - Rituximab
KW  - Treatment Outcome
KW  - Vincristine
N1  - Publication Type: Clinical Trial, Phase II; Journal Article; Multicenter Study
UR  - https://doi.org/10.3109/10428194.2013.790544
ER  -